PTSD

A new study found probable PTSD was prevalent among adults in the community after a mass shooting, with greater prevalence among those previously assaulted.

Dunlop discusses what the next steps for MDMA-assisted therapy would be if approved.

Family physician Scuderi shares how he helps patients manage PTSD symptoms ahead of Fourth of July fireworks.

FDA accepts a supplemental New Drug Application for brexpiprazole in combination with sertraline for the treatment of adults with PTSD, with a PDUFA date of February 8, 2025.

The study APEX-002-B01-02 will evaluate how APEX-52, a microdose psilocybin, can impact safe driving.

Follow HCPLive's coverage of the full-day FDA committee meeting regarding Lykos Therapeutics' application for MDMA-assisted therapy as a novel treatment for patients with PTSD.

Emerson previews the highly anticipated FDA advisory committee this week, and Lykos' plans for rolling out MDMA-assisted therapy in the event it is approved to treat PTSD.

New data presented at SLEEP 2024 show sleep disorders including insomnia are only linked to worse quality of life when veterans do not also have PTSD.

The FDA will decide on an application this summer for the treatment of PTSD with MDMA-assisted therapy. A renowned researcher explains how the treatment benefits patients with trauma.

The new psychedelic CPT codes, effective January 1, 2024, could impact MDMA if approved. The FDA's Psychopharmacologic Drugs Advisory Committee will discuss MDMA on June 4.

Compass Pathways reports positive results for psilocybin in PTSD treatment, showing safety and symptom improvement in an open-label phase 2 study.

Lykos Therapeutics' new drug application for MDMA plus psychiatric intervention for adults with PTSD will be the first reviewed by an FDA committee for such a therapy.

Marmar explains what anticipated blood and molecular profiling of PTSD may provide psychiatrists treating patients.

New literature review data suggests doxazosin is related to less incident hypotension than prazosin, while providing clinical benefit, in PTSD patients with condition-related nightmares.

A new study found individuals with PTSD face rapid transitions between neutral and negative emotional states.

Lykos Therapeutics announced the FDA accepted its NDA for MDMA-assisted therapy for individuals with PTSD on February 9, 2024, backed by phase 3 data showing the drug’s efficacy.

The study found the odds of a perinatal PTSD diagnosis were greater for people aged 15 – 26 years, more comorbidities, and a lower income of poverty.

This March 2024 psychiatry month in review highlights positive phase 2b and phase 2a data for drugs targeting treatment-resistant depression, generalized anxiety disorder, and PTSD.

Bionomics announced the release of the full dataset analysis of the ATTUNE phase 2b trial; the data suggests BNC210 for PTSD could have an advantage over approved medications.

A new study found crisis response planning for PTSD among military veterans had lower onset of suicidal ideation than veterans with self-guided safety planning.

Jennifer Mitchell, PhD, discusses MAPS Public Benefit Corporations’ recent New Drug Application submission for MDMA-Assisted Therapy for PTSD and what the treatment’s potential approval could mean for people with PTSD.

A new study found that 25% of PSG-PTSD were related to metabolic traits.

Participants with PTSD in a new study heard voices more significantly than did patients with schizophrenia and schizoaffective disorder, according to investigators.

Investigators systematically review data to further understand the relationship between sleep and PTSD as it impacts treatment outcomes.